Psychiatr. praxi. 2013;14(3):123-126

Safety monitoring of the treatment with risperidone in children and adolescents.

prof.MUDr.Ivana Drtílková, CSc.
Psychiatrická klinika FN Brno a Lékařská fakulta Masarykovy univerzity, Brno

Risperidone is an atypic antipsychotic frequently used in children. Risperidone was found to be beneficial and safe in low doses in the

treatment of conduct disorders in children and adolescents. Studies in children report significant weight gain and increase in BMI, extrapyramidal

side effects and variable elevation in prolactin levels, especially in long term risperidone use. Guidelines of Canadian Alliance

for Monitoring Effectiveness and Safety of Antipsychotics in Children (CAMESA) are specifically focused on metabolic and neurological

side effects, and how they should be monitored.

Key word: risperidone, metabolic, neurological, extrapyramidal side effects, monitoring.

Keywords: risperidon, metabolické, neurologické, extrapyramidové nežádoucí účinky, monitoring

Published: August 7, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Drtílková I. Safety monitoring of the treatment with risperidone in children and adolescents. Psychiatr. praxi. 2013;14(3):123-126.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Zito JM, Derivan AT, Kratochvil CJ, et al. Off-label psychopharmacologic prescribing for Children: History supports close clinical monitoring.Child Adol Psychiatry Mental Health 2008; 2: 24. Go to original source... Go to PubMed...
    2. Cooper WO, Arbogast PG, Ding H, et al. Trends in prescribing of antipsychotic medications for US children. Ambul Pediatr 2006; 6(2): 79-83. Go to original source... Go to PubMed...
    3. Drtílková I, Hrdlička, Paclt I. Hyperkinetické poruchy(ADHD) u dětí. In: Raboch et al. Doporučené postupy psychiatrické péče III. Tribun EU 2010: 219-224.
    4. McKinney C, Renk K. Atypical antipsychotic medications in the management of disruptive behaviors in children: safety guidelines and recommendations. Clin Psychol Rev. 2011; 31(3): 465-471. Go to original source... Go to PubMed...
    5. Calarge CA, Ellingrod VL, Zimmerman B, Acion L, Sivitz WI, Schlechte JA.Leptin gene-2548G/A variants predict risperidone-associated weight gain in children and adolescents. Psychiatr Genet. 2009; 19(6): 320. Go to original source... Go to PubMed...
    6. Hoekstra PJ, Troost PW, Lahuis B, et al. Risperidone-Induced Weight Gain in Referred Children with Autism Spectrum. Disorders Is Associated with a Common Polymorphism in the 5-Hydroxytryptamine 2C Receptor Gene J Child Adolesc Psychopharmacol. 2010; 20(6): 473-477. Go to original source... Go to PubMed...
    7. Devlin AM, Ngai ZF, Ronsley R, Panagiotopoulos C. Cardiometabolic risk and the MTHFR C677T variant in children treated with second-generation antipsychotics.Translational Psychiatry 2012; 2: e71. Go to original source...
    8. Correll Ch, Lencz T, Malhotra A. Antipsychotic drugs and obesity.Trends in molecular medicine 2011; 2(17): 97-107. Go to original source... Go to PubMed...
    9. Maayan LA, Vakhrusheva J. Risperidone associated weight, leptin, and anthropometric changes in children and adolescents with psychotic disorders in early treatment Human Psychopharmacology: Clinical and Experimental 2010; 25(2): 133-138. Go to original source... Go to PubMed...
    10. Baker JL, Olsen LW, S?rensen TI. Childhood body-mass index and the risk of coronary heart disease in adulthood. N Engl J Med. 2007; 357(23): 2329-2337. Go to original source... Go to PubMed...
    11. Juonala M, Juhola J, Magnussen, et al. Childhood Environmental and Genetic Predictors of Adulthood Obesity: The Cardiovascular Risk in Young Finns StudyJ Clin Endocrinol Metab. 2011; 96(9): E1542-E1549. Go to original source... Go to PubMed...
    12. Pulkki-R?back L, Elovainio M, Kivimäki M, Mattsson N. Depressive symptoms and the metabolic syndrome in childhood and adulthood: a prospective cohort study. Health Psychol. 2009; 28(1): 108-116. Go to original source... Go to PubMed...
    13. Correll C. Monitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients. International Review of Psychiatry 2008; 20(2): 195-201. Go to original source... Go to PubMed...
    14. Pappagallo M, Silva R. The effect of atypical antipsychotic agents on prolactin levels in children and adolescents. J Child Adolesc Psychopharmacol 2004; 14(3): 359-371. Go to original source... Go to PubMed...
    15. Croonenberghs J, Fegert JM, Findling RL. Risperidone in children with disruptive behavior disorders and subaverage intelligence: A 1-year, open-label study of 504 patients. Journal of the American Academy of Child and Adolescent Psychiatry 2005; 41(1): 64-72. Go to original source... Go to PubMed...
    16. Pringsheim T, Doj A, Belanger S.Treatment recommendations for extrapyramidal side effects associated with second generation antipsychotic use in children and youth. Paediater Child Health 2011; 16(9): 590-599. Go to original source...
    17. Pringsheim T, Panagiotopoulos C Davidson J, CAMESA guideline group et al. Evidence-Based Recommendations for Monitoring Safety ofSecond Generation Antipsychotics in Children and Youth J Can Acad Child Adolesc Psychiatry. 2011; 20(3): 218-233.

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.